Indications |
Oral Cough Adult: 200-400 mg every 4 hr. Max: 2.4 g/day. Child: 6-12 yr: 100-200 mg; 2-6 yr: 50-100 mg; 6 mth-2 yr: 25-50 mg. To be given every 4 hr. Max: 6-12 yr: 1.2 g/day; 2-5 yr: 600 mg/day. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Persistent cough e.g. occurs with smoking, asthma, chronic bronchitis, or emphysema; cough accompanied by excessive secretions; cough with a fever, rash, or persistent headache; Pregnancy, lactation. Porphyria. |
Adverse Reactions |
GI discomfort, nausea and vomiting; dizziness, drowsiness, headache; rash; decreased uric acid levels; urinary calculi (large doses). |
Lab Interactions |
Possible color interference with determination of 5-HIAA and VMA; discontinue for 49 hrs prior to test. |
Mechanism of Actions |
Guaifenesin increases the volume and reduce the viscosity of tenacious sputum and is used as an expectorant for productive cough. Absorption: Well absorbed in the GI tract. Excretion: Urine. |
ATC Classification |
R05CA03 - guaifenesin ; Belongs to the class of expectorants. Used in the treatment of wet cough. |
Available As |
|
Guaifenesin (Guaiphenesin/Gyceral Guaiacolate)
Post Review about Guaifenesin (Guaiphenesin/Gyceral Guaiacolate) Click here to cancel reply.
Guaifenesin (Guaiphenesin/Gyceral Guaiacolate) Containing Brands
Guaifenesin (Guaiphenesin/Gyceral Guaiacolate) is used in following diseases
Drug - Drug Interactions of Guaifenesin (Guaiphenesin/Gyceral Guaiacolate)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.